Pharmacies

• FDA kondigde nieuwe handhavingsmaatregelen aan gericht tegen compounding apotheken die GLP-1-geneesmiddelen zoals semaglutide produceren vanwege veiligheidsproblemen. • De aanpak richt zich op de risico's van niet-goedgekeurde versies van afslank- en diabetesmedicatie die de markt overspoelen. • Deze beleidswijziging is bedoeld om patiënten te beschermen tegen mogelijke contaminatie en doseringsfouten in de booming GLP-1-sector van 100 miljard dollar.

• The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions. • Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment. • The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.

As outbreak in Kent claims the lives of two young people, experts advise against rushing to get a vaccinePharmacies in England are reporting a surge in demand for meningitis vaccines after an outbreak in Kent claimed the lives of two young people and left others in hospital.However experts have advised against rushing to get a jab, stressing public health authorities are best placed to determine if vaccinations are required – and for whom. Continue reading...